Testing a targeted radiation drug plus a DNA repair blocker
Part of Cancer clinical trials.
This early-phase trial tests whether combining a targeted radiation medicine (177Lu-TLX250) with a DNA repair–blocking drug (peposertib) can shrink advanced solid tumors. It is designed for tumors that strongly show a marker called CAIX, which helps the radiation home in and may make treatment more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic solid cancer that has gotten worse after standard treatment, or you can’t have (or don’t want) standard treatment that’s usually offered
- Your scans show at least one measurable tumor spot on CT/MRI, and it lights up on a CAIX-targeting scan (89Zr-TLX250 uptake)
- Your tumors must be CAIX-positive in at least 75% of the tumor volume (strong enough uptake compared with normal liver)
- You’re well enough to do daily activities (ECOG 0–1) and have about 6 months or more of expected life
- You have acceptable blood counts and organ function for study treatment
- You haven’t had prior CAIX-targeting therapy or prior treatment with 177Lu-TLX250 or similar radioligand therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called [177Lu]Lu-XT117, which delivers a small dose of radiation directly to cancer cells that have a specific protein called FAP. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for people with advanced clear cell renal cell carcinoma that has returned or not responded to at least 2 prior treatments.
This trial tests a new radioactive drug, Lutetium-177 FAP-75, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and deliver radiation directly to cancer cells, potentially slowing tumor growth.
This Phase 1 trial tests how safe and effective two anti-cancer drugs (peposertib and tuvusertib) are for advanced solid tumors. It focuses on cancers with specific DNA repair and cell-growth gene changes, aiming to shrink tumors and improve outcomes when standard treatments have stopped working.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.